| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3818 |
| Trial ID | NCT06333483 |
| Disease | Systemic Lupus Erythematosus |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | obe-cel|Obecabtagene autoleucel|AUTO1 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Single-Arm, Open-Label, Phase I Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients With Severe, Refractory Systemic Lupus Erythematosus |
| Year | 2024 |
| Country | Spain|United Kingdom |
| Company sponsor | Autolus Limited |
| Other ID(s) | AUTO1-SL1|2023-508236-60-00 |
| Cohort 1 | |||||||||||
|
|||||||||||